NASDAQ:INVA Innoviva (INVA) Stock Price, News & Analysis $18.49 -0.54 (-2.84%) Closing price 11/16/2026 04:00 PM EasternExtended Trading$18.50 +0.01 (+0.05%) As of 11/16/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Innoviva Stock (NASDAQ:INVA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Innoviva alerts:Sign Up Key Stats Today's Range$18.41▼$19.2450-Day Range$18.49▼$21.4552-Week Range$18.41▼$25.15Volume814,143 shsAverage Volume861,615 shsMarket Capitalization$1.31 billionP/E Ratio5.47Dividend YieldN/APrice Target$39.00Consensus RatingModerate Buy Company Overview Innoviva, Inc. is a biopharmaceutical company with two main areas of activity: royalty interests in respiratory medicines developed with GSK and the development and commercialization of specialty medicines. Its respiratory-related royalties include products such as Trelegy Ellipta, Anoro Ellipta and Breo Ellipta, which are used to treat chronic obstructive pulmonary disease and asthma and are marketed by GSK. Through its specialty therapeutics operations, Innoviva focuses on medicines for serious infections and other acute-care conditions. Its portfolio includes products such as Xenleta and Xacduro for certain bacterial infections, Xerava for complicated intra-abdominal infections, and Giapreza for dangerously low blood pressure in adults with septic or other distributive shock. The company was formerly known as Theravance, Inc. and adopted the Innoviva name in 2015, following the separation of Theravance Biopharma. Innoviva’s products and royalty arrangements give it a presence in markets beyond the United States, though the geographic reach varies by product and commercial partner.AI Generated. May Contain Errors. Read More Innoviva Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreINVA MarketRank™: 3.579621232325 of 5 starsInnoviva scored higher than 72% of companies evaluated by MarketBeat, and ranked 187th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingInnoviva has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialInnoviva has a consensus price target of $39.00, representing about 110.9% upside from its current price of $18.49.Amount of Analyst CoverageInnoviva has only been the subject of 3 research reports in the past 90 days.Read more about Innoviva's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth38.16% Earnings GrowthEarnings for Innoviva are expected to grow by 38.16% in the coming year, from $1.52 to $2.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Innoviva is 5.47, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.84.Price to Earnings Ratio vs. SectorThe P/E ratio of Innoviva is 5.47, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.36.Price to Earnings Growth RatioInnoviva has a PEG Ratio of 4.15. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioInnoviva has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.59% of the float of Innoviva has been sold short.Short Interest Ratio / Days to CoverInnoviva has a short interest ratio ("days to cover") of 12.88, which indicates bearish sentiment.Change versus previous monthShort interest in Innoviva has recently increased by 3.16%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInnoviva does not currently pay a dividend.Dividend GrowthInnoviva does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.02 News SentimentInnoviva has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Innoviva this week, compared to 3 articles on an average week.Search Interest2 people have searched for INVA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Innoviva to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Innoviva insiders have not sold or bought any company stock.Percentage Held by Insiders2.01% of the stock of Innoviva is held by insiders.Percentage Held by Institutions99.12% of the stock of Innoviva is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Innoviva's insider trading history. Receive INVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INVA Stock News HeadlinesInnoviva (NASDAQ:INVA) & Teva Pharmaceutical Industries (NYSE:TEVA) Critical Contrast1 hour ago | americanbankingnews.comIs Quarterly Loss Altering The Investment Case For Innoviva Stock (INVA)?November 16 at 7:08 PM | finance.yahoo.comA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years. | Profits Run (Ad)HC Wainwright Issues Negative Forecast for Innoviva EarningsNovember 16 at 1:43 AM | americanbankingnews.comInnoviva, Inc. (NASDAQ:INVA) Stock Rated "Moderate Buy" by Wall Street BrokeragesNovember 9, 2026 | americanbankingnews.comInnoviva (NASDAQ:INVA) Price Target Cut to $34.00 by Analysts at OppenheimerNovember 6, 2026 | americanbankingnews.comOppenheimer Trims Price Target on Innoviva to $34 From $35, Keeps Outperform RatingNovember 5, 2026 | marketscreener.comMInnoviva, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 4, 2026 | marketscreener.comMSee More Headlines INVA Stock Analysis - Frequently Asked Questions How have INVA shares performed this year? Innoviva's stock was trading at $19.99 at the beginning of the year. Since then, INVA stock has decreased by 7.5% and is now trading at $18.49. How were Innoviva's earnings last quarter? Innoviva, Inc. (NASDAQ:INVA) issued its quarterly earnings data on Wednesday, November, 4th. The biotechnology company reported ($1.03) earnings per share for the quarter, missing analysts' consensus estimates of $0.52 by $1.55. The biotechnology company had revenue of $106.12 million for the quarter, compared to the consensus estimate of $115.31 million. Innoviva had a trailing twelve-month return on equity of 22.91% and a net margin of 44.13%. Who are Innoviva's major shareholders? Innoviva's top institutional investors include State Street Corp (4.84%), Goldman Sachs Group Inc. (2.28%), Royce & Associates LP (1.55%) and William Blair Investment Management LLC (1.15%). View institutional ownership trends. How do I buy shares of Innoviva? Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Innoviva own? Based on aggregate information from My MarketBeat watchlists, some other companies that Innoviva investors own include NVIDIA (NVDA), Micron Technology (MU), Intel (INTC), Advanced Micro Devices (AMD), Tesla (TSLA), Exelixis (EXEL) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings11/04/2026Today11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 12 days, INVA's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:INVA Previous SymbolNASDAQ:THRX CIK1080014 Webwww.inva.com Phone(650) 238-9600Fax650-827-8690Employees159Year Founded1996Price Target and Rating Average Price Target for Innoviva$39.00 High Price Target$46.00 Low Price Target$34.00 Potential Upside/Downside+110.9%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$1.99 Trailing P/E Ratio5.47 Forward P/E Ratio8.80 P/E Growth4.15Net Income$271.17 million Net Margins44.13% Pretax Margin51.10% Return on Equity22.91% Return on Assets16.67% Debt Debt-to-Equity Ratio0.23 Current Ratio15.44 Quick Ratio14.58 Sales & Book Value Annual Sales$411.33 million Price / Sales3.20 Cash Flow$4.90 per share Price / Cash Flow3.77 Book Value$16.00 per share Price / Book1.16Miscellaneous Outstanding Shares71,080,000Free Float69,652,000Market Cap$1.31 billion OptionableOptionable Beta0.38 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:INVA) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredA Nasdaq drone company just landed a deal with a Philippine billionaire's groupA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innoviva, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innoviva With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.